(R)-Baclofen
(R)-Baclofen Uses, Dosage, Side Effects, Food Interaction and all others data.
(R)-Baclofen, or STX209, is the R-enantiomer of baclofen. It is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind, placebo controlled trials. It has also been investigated as a treatment for spasticity due to multiple sclerosis and spinal cord injury. (R)-Baclofen was investigated as a treatment for gastroesophageal reflux disease (GERD); however, with disappointing results.
Trade Name | (R)-Baclofen |
Generic | Arbaclofen |
Arbaclofen Other Names | (R)-Baclofen, Arbaclofen |
Type | |
Formula | C10H12ClNO2 |
Weight | Average: 213.661 Monoisotopic: 213.05565634 |
Groups | Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated in clinical trials as a potential treatment for spasticity in multiple sclerosis, autism spectrum disorder, and social withdrawal in fragile X syndrome.
How (R)-Baclofen works
(R)-Baclofen, or R-baclofen, acts upstream of the mGluR5 receptor to increase inhibitory neurotransmission. It is the isomer of baclofen which harbors antispastic activity.
Elimination Route
Unlike baclofen, absorption of arbaclofen is not limited to the upper small intestine. (R)-Baclofen can also be absorbed in the lower small intestine and the colon, allowing for the development of sustained release formulations.
Clearance
Blood clearance of an IV bolus of R-baclofen in rats, monkeys, and dogs, resulted in a half life of 1.6-3.4hours, in one study. Total blood clearance was reported to be 0.51±0.13L/h/kg in rats, 0.31±0.11L/h/kg in monkeys, and 0.24±0.01L/h/kg in dogs. (2)
Elimination Route
>80% of R-baclofen is renally eliminated unchanged.
Innovators Monograph
You find simplified version here (R)-Baclofen